Friedenthal Financial Buys New Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Friedenthal Financial bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 184 shares of the biopharmaceutical company’s stock, valued at approximately $51,000.

A number of other institutional investors have also recently made changes to their positions in the business. SteelPeak Wealth LLC raised its holdings in Alnylam Pharmaceuticals by 147.7% during the first quarter. SteelPeak Wealth LLC now owns 6,860 shares of the biopharmaceutical company’s stock worth $1,025,000 after purchasing an additional 4,090 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares in the last quarter. Quattro Financial Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 2,517.8% in the first quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock valued at $747,000 after buying an additional 4,809 shares during the last quarter. Maryland State Retirement & Pension System lifted its stake in shares of Alnylam Pharmaceuticals by 4.1% during the 1st quarter. Maryland State Retirement & Pension System now owns 9,836 shares of the biopharmaceutical company’s stock worth $1,441,000 after purchasing an additional 385 shares during the period. Finally, Yousif Capital Management LLC boosted its stake in Alnylam Pharmaceuticals by 9.7% in the 1st quarter. Yousif Capital Management LLC now owns 1,635 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 144 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ALNY. TD Cowen lifted their target price on Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. Barclays raised their target price on shares of Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, October 10th. Bank of America boosted their price objective on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Finally, Leerink Partners increased their target price on Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a “market perform” rating in a research note on Tuesday, June 25th. Six equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $286.82.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the sale, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Dennis A. Ausiello sold 20,250 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the sale, the director now directly owns 136 shares in the company, valued at approximately $35,632. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $20,563,480. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,398 shares of company stock valued at $13,595,460 in the last 90 days. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $295.93 on Friday. The firm has a market cap of $37.43 billion, a P/E ratio of -110.42 and a beta of 0.39. The stock’s 50-day moving average is $271.29 and its two-hundred day moving average is $215.60. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. During the same period in the previous year, the company earned ($2.21) EPS. The firm’s revenue for the quarter was up 107.0% compared to the same quarter last year. On average, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.